Dashboard
Manage Tickers

LRMRLarimar Therapeutics, Inc.

Nasdaq larimartx.com


$ 8.00 $ 0.90 (12.68 %)    

Friday, 31-May-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 8
$ 7.55
$ 7.98 x 100
$ 8.30 x 400
$ 7.55 - $ 8.21
$ 2.18 - $ 13.68
1,013,617
na
428.43M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-05-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-14-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-10-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-15-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-25-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-sentinelone-shares-are-trading-lower-by-16-here-are-other-stocks-moving-in-fridays-mid-day-session
Why SentinelOne Shares Are Trading Lower B...
05/31/2024 17:17:02

jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target
JMP Securities Reiterates Market Outperfor...
05/31/2024 15:46:26

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

ambarella-posts-upbeat-results-joins-gap-pagerduty-elastic-and-other-big-stocks-moving-higher-on-friday
Ambarella Posts Upbeat Results, Joins Gap,...
05/31/2024 14:40:33

larimar-therapeutics-selected-by-fda-to-participate-in-support-for-clinical-trials-advancing-rare-disease-therapeutics-pilot-program-for-nomlabofusp-in-friedreichs-ataxia
Larimar Therapeutics Selected By FDA To Pa...
05/30/2024 20:35:28

START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medi...

hello-group-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Hello Group And Other Big Stocks Moving Lo...
05/28/2024 09:45:35

citigroup-maintains-buy-on-larimar-therapeutics-raises-price-target-to-14
Citigroup Maintains Buy on Larimar Therape...
05/22/2024 17:50:00

Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from...

larimar-therapeutics-friedreichs-ataxia-investigational-drug-differentiated-from-biogens-marketed-drug
Larimar Therapeutics' Friedreich's Ataxia ...
05/21/2024 18:39:04

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...

why-james-hardie-industries-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why James Hardie Industries Shares Are Tra...
05/21/2024 17:36:28

jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target
JMP Securities Reiterates Market Outperfor...
05/21/2024 16:37:06

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

xpeng-posts-strong-results-joins-larimar-therapeutics-transcat-and-other-big-stocks-moving-higher-on-tuesday
XPeng Posts Strong Results, Joins Larimar ...
05/21/2024 14:38:35

why-larimar-therapeutics-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket
Why Larimar Therapeutics Shares Are Tradin...
05/21/2024 12:12:19

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/21/2024 12:06:31

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/20/2024 20:31:10

fda-removed-partial-clinical-hold-for-larimar-therapeutics-nomlabofusp-program-in-friedreichs-ataxia
FDA Removed Partial Clinical Hold For Lari...
05/20/2024 20:07:04

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study dataOngoing...

larimar-therapeutics-cash-cash-equivalents-and-marketable-securities-of-239m-as-of-march-31-2024-extends-projected-cash-runway-into-2026
Larimar Therapeutics' Cash, Cash Equivalen...
05/09/2024 11:39:00

larimar-therapeutics-q1-2024-gaap-eps-027-beats-028-estimate
Larimar Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:38:09

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of ...

leerink-partners-initiates-coverage-on-larimar-therapeutics-with-outperform-rating-announces-price-target-of-25
Leerink Partners Initiates Coverage On Lar...
04/03/2024 13:18:00

Leerink Partners analyst Joori Park initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and an...

jmp-securities-reiterates-market-outperform-on-larimar-therapeutics-maintains-25-price-target
JMP Securities Reiterates Market Outperfor...
03/15/2024 14:37:46

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...

recap-larimar-therapeutics-q4-earnings
Recap: Larimar Therapeutics Q4 Earnings
03/14/2024 21:15:07

larimar-therapeutics-q4-eps-030-misses-025-estimate-cash-position-868m
Larimar Therapeutics Q4 EPS $(0.30) Misses...
03/14/2024 20:15:18

Larimar Therapeutics (NASDAQ: LRMR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION